MK-677 (Ibutamoren) vs Tesamorelin + Ipamorelin
A side-by-side research comparison of MK-677 (Ibutamoren) and Tesamorelin + Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MK-677 (Ibutamoren) | Tesamorelin + Ipamorelin |
|---|---|---|
| Full name | Ibutamoren Mesylate (MK-677) | Tesamorelin/Ipamorelin Combination |
| Category | Growth Hormone | Growth Hormone |
| Status | Investigational | Compounded combination |
| Mechanism | Acts as ghrelin mimetic at GHS-R1a receptors in hypothalamus and pituitary. Excellent oral bioavailability and 24-hour duration. | Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility. |
| Molecular weight | 528.7 Da | Blend |
| Half-life | 24 hours | Tesamorelin: ~26 min; Ipamorelin: ~2 hours. Combined peak GH at 30-60 min post-injection. |
| Bioavailability | High (oral) | High (subcutaneous) |
| Typical dose | 10-25 mg | Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg |
| Frequency | Once daily | Once daily (before bed) or twice daily |
| Route | Oral (capsule/liquid) | Subcutaneous injection |
MK-677 (Ibutamoren) reported benefits
- Oral administration
- Sustained 24h GH elevation
- Increased IGF-1
- Improved sleep depth
- Enhanced recovery
- Bone density support
Tesamorelin + Ipamorelin reported benefits
- Significant fat loss (especially visceral/abdominal)
- Lean muscle gains
- Improved sleep quality
- Enhanced recovery
- Anti-aging effects
- Better body composition without exogenous HGH side effects
Related comparisons
Research and educational reference only. Not medical advice.